Biora
This article was originally published in The Gray Sheet
Executive Summary
Plans to launch its PrefGel in the third quarter of 1998 following recent FDA clearance, the company says June 3. PrefGel, which is to be used by periodontists for conditioning exposed root surfaces during periodontal surgery, received European approval under the name PrepHgel earlier this year. PrefGel is the company's second dental therapy to reach the market. Its first product, Emdogain, for treatment of intrabony defects, was approved in 1996 ("The Gray Sheet" Oct. 21, 1996, I&W-4)...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.